Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, NY 10032-3784, USA.
Lab Invest. 2011 Jan;91(1):63-84. doi: 10.1038/labinvest.2010.151. Epub 2010 Aug 9.
Patients with acute kidney injury (AKI) frequently suffer from extra-renal complications including hepatic dysfunction and systemic inflammation. We aimed to determine the mechanisms of AKI-induced hepatic dysfunction and systemic inflammation. Mice subjected to AKI (renal ischemia reperfusion (IR) or nephrectomy) rapidly developed acute hepatic dysfunction and suffered significantly worse hepatic IR injury. After AKI, rapid peri-portal hepatocyte necrosis, vacuolization, neutrophil infiltration and pro-inflammatory mRNA upregulation were observed suggesting an intestinal source of hepatic injury. Small intestine histology after AKI showed profound villous lacteal capillary endothelial apoptosis, disruption of vascular permeability and epithelial necrosis. After ischemic or non-ischemic AKI, plasma TNF-α, IL-17A and IL-6 increased significantly. Small intestine appears to be the source of IL-17A, as IL-17A levels were higher in the portal circulation and small intestine compared with the levels measured from the systemic circulation and liver. Wild-type mice treated with neutralizing antibodies against TNF-α, IL-17A or IL-6 or mice deficient in TNF-α, IL-17A, IL-17A receptor or IL-6 were protected against hepatic and small intestine injury because of ischemic or non-ischemic AKI. For the first time, we implicate the increased release of IL-17A from small intestine together with induction of TNF-α and IL-6 as a cause of small intestine and liver injury after ischemic or non-ischemic AKI. Modulation of the inflammatory response and cytokine release in the small intestine after AKI may have important therapeutic implications in reducing complications arising from AKI.
患有急性肾损伤(AKI)的患者常伴有肾外并发症,包括肝功能障碍和全身炎症。我们旨在确定 AKI 诱导的肝功能障碍和全身炎症的机制。AKI(肾缺血再灌注(IR)或肾切除)小鼠迅速发展为急性肝功能障碍,并遭受明显更严重的肝 IR 损伤。在 AKI 后,观察到快速门脉周围肝细胞坏死、空泡化、中性粒细胞浸润和促炎 mRNA 上调,提示肝损伤的肠源。AKI 后的小肠组织学显示绒毛乳糜毛细血管内皮细胞凋亡、血管通透性破坏和上皮坏死。在缺血性或非缺血性 AKI 后,血浆 TNF-α、IL-17A 和 IL-6 显著增加。小肠似乎是 IL-17A 的来源,因为门静脉循环和小肠中的 IL-17A 水平高于从全身循环和肝脏测量到的水平。用针对 TNF-α、IL-17A 或 IL-6 的中和抗体或 TNF-α、IL-17A、IL-17A 受体或 IL-6 缺陷的野生型小鼠治疗可防止缺血性或非缺血性 AKI 引起的肝和小肠损伤。我们首次表明,缺血性或非缺血性 AKI 后从小肠释放的增加的 IL-17A 与 TNF-α和 IL-6 的诱导一起作为小肠和肝脏损伤的原因。AKI 后小肠中炎症反应和细胞因子释放的调节可能对减少 AKI 引起的并发症具有重要的治疗意义。